首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Effects of ginsenoside Rg3 on bone loss, bone mineral density and osteoclast number in glucocorticoid-induced osteoporosis rats, and the likely mechanism of action
【24h】

Effects of ginsenoside Rg3 on bone loss, bone mineral density and osteoclast number in glucocorticoid-induced osteoporosis rats, and the likely mechanism of action

机译:人参皂苷RG3对糖皮质激素诱导的骨质疏松大鼠骨质损失,骨密度和骨细胞数的影响,以及可能的作用机制

获取原文
           

摘要

Purpose: To investigate the effect of ginsenoside Rg3 on bone loss, bone mineral density (BMD) and osteoclast number in glucocorticoid-induced osteoporosis (GIOP) rats, and the mechanism of action involved. Methods: Sixty female Wistar rats were assigned to control, model group, ginsenoside Rg3, and alendronate sodium groups, comprised of 15 rats per group. The osteoporosis rat model was established via intramuscular injection of dexamethasone. Changes in bone mineral content (BMC), BMD trabecular thickness and area, osteoblasts and osteoclasts in femurs and lumbar vertebrae were measured after 3 months of treatment. Results: There were significantly higher BMC and BMD levels in ginsenoside Rg3 group than in alendronate rats (p 0.05). There were marked increases in osteoblasts, and marked decreases in osteoclasts in the ginsenoside Rg3 group, alendronate sodium and control rats, relative to model rats (p 0.05). Conclusion: Ginsenoside Rg3 arrests bone loss, and enhances bone density, trabecular thickness and area, bone microstructure, osteoblast activity and population of osteoclasts number in glucocorticoid-induced osteoporotic rats. This provides a new research direction for the clinical treatment of osteoporosis.
机译:目的:探讨人参皂苷RG3对糖皮质激素诱导的骨质疏松症(GIOP)大鼠骨质损失,骨密度(BMD)和骨细胞数的影响,以及所涉及的作用机制。方法:分配60只雌性Wistar大鼠对每组15只大鼠组成的控制,模型组,人参皂苷RG3和Alendronate钠组。通过肌内注射地塞米松建立骨质疏松大鼠模型。骨矿物质含量(BMC),BMD毛细管厚度和面积,骨质细胞和骨质细胞和骨质体,治疗3个月后测量骨质细胞和腰椎。结果:人参皂甙RG3组中的BMC和BMD水平显着高于醛膦大鼠(P 0.05)。骨细胞的显着增加,相对于模型大鼠,人参皂苷RG3组,阿仑膦酸盐钠和对照大鼠的骨细胞中显着降低(P <0.05)。结论:人参皂甙RG3抑制骨质损失,增强糖皮质激素诱导的骨质疏松大鼠骨密度,骨密度,厚度和面积,骨显微组织,骨细胞骨质细胞数量,骨质形成数。这为骨质疏松症的临床治疗提供了一种新的研究方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号